Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions
The new agreement is based off the Master Services Agreement that both companies entered in 2021 for the development, manufacture, and supply of rhenium (186Re) obisbemeda, according to a press release.
On May 2, 2023, Plus Therapeutics, Inc. announced the continuation of its collaboration with Piramal Pharma Solutions (PPS) to produce additional current good manufacturing practice (CGMP) liposome intermediate drug product to meet the increase in demand for its lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, for ongoing and planned clinical trials.
Rhenum (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver highly targeted high-dose radiation in central nervous system (CNS) tumors in a safe, effective, and convenient manner to optimize patient outcomes, according to the press release. Further, it has the potential to reduce risks and improve outcomes for CNS cancer patients versus currently approved therapies with a more targeted and potent radiation dose, according to the company.
The new agreement is based off the Master Services Agreement that both companies entered in 2021 for the development, manufacture, and supply of rhenium (186Re) obisbemeda, according to a press release.
“We significantly grew our clinical trial programs for central nervous system cancers in 2022 and we expect to continue this momentum into 2023,” said Marc H. Hedrick, MD, president and chief executive officer of Plus Therapeutics, in the press release. “Our strategic partnership with PPS will support our robust supply chain and manufacturing processes to keep ahead of our planned clinical development expansion and lay the groundwork for commercialization in the future.”
Source: Plus Therapeutics
